Hypogonadism – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Hypogonadism Market Outlook

Thelansis’s “Hypogonadism Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypogonadism treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hypogonadism Overview

Hypogonadism in men, defined by a low serum testosterone concentration, causes a slew of symptoms such as decreased libido, erectile dysfunction, reduced ejaculate volume, loss of body and facial hair, weakness, decreased lean body mass, reduced bone density, increased body fat, fatigue, and anemia. Most notably, libido loss and erectile dysfunction (ED). Depressive symptoms, decreased cognitive abilities, irritability, and lethargy or energy loss are also signs of low testosterone. Endogenous testosterone deficiency also has a negative impact on bone mass and is a significant risk factor for osteoporosis in men. Progressive loss of muscle mass and strength and testicular dysfunction often results in impaired sperm production. Unlike female menopause, which is a universal and abrupt aging process, not all men become testosterone deficient as they age. Even in their advanced years, a significant number of men remain eugonadal. However, as men age, they become increasingly likely to have conditions, such as cardiovascular disease, depression, osteoporosis, and diabetes, that occur concomitantly with decreased testosterone levels.

• The prevalent cases of Hypogonadism affect an estimated 4 to 5 million men in the United States, although it may occur in men at any age.
• Hypogonadism was found in 2.1 percent to 12.8 percent of middle-aged to older men in the general population, with an estimated incidence of 12 new cases per 1,000 people per year.
• Patients with comorbid conditions, such as type 2 diabetes mellitus and obesity, had a higher prevalence. Approximately 10–12% of men with Hypogonadism were being treated with testosterone.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: